Observational Study of Corticosteroid Phobia Using the TOPICOP Score among Adults and Caregivers of Children with Atopic Dermatitis in Japan.

IF 4.2 3区 医学 Q1 DERMATOLOGY
Dermatology and Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-16 DOI:10.1007/s13555-025-01439-6
Takeshi Nakahara, Hiroyuki Murota, Shinichi Noto, Miyuki Matsukawa, Rikiya Toda, Yasuhito Konishi, Daisaku Michikami
{"title":"Observational Study of Corticosteroid Phobia Using the TOPICOP Score among Adults and Caregivers of Children with Atopic Dermatitis in Japan.","authors":"Takeshi Nakahara, Hiroyuki Murota, Shinichi Noto, Miyuki Matsukawa, Rikiya Toda, Yasuhito Konishi, Daisaku Michikami","doi":"10.1007/s13555-025-01439-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Topical corticosteroid (TCS) phobia, which tends to interfere with the continuation of TCS treatment for atopic dermatitis (AD), has not been elucidated in Japan using the topical corticosteroid phobia (TOPICOP) scale. We aimed to clarify TCS phobia among patients with AD in Japan and evaluate its relationship with AD conditions.</p><p><strong>Methods: </strong>This observational study, using the database of health receipt (between October 2021 and October 2022) and online questionnaire (conducted in October 2022) data, included adult respondents with and without AD and caregivers who responded to the questionnaire about their children aged ≤ 18 years, with and without AD. The TOPICOP scores measuring TCS phobia were summarized and compared according to AD severity, consultation with a doctor, and presence of AD using an analysis of covariance (ANCOVA) model (covariates: sex and age).</p><p><strong>Results: </strong>In this study, 1507 adults with AD and 525 caregivers of children with AD were included. Among adults with AD, the mean TOPICOP score (± standard deviation) was 42.5 ± 18.9, while it was 41.7 ± 18.6 among caregivers of children with AD. Of the three TOPICOP domains (knowledge and beliefs, fears, and behaviors), the fear domain questions showed the highest percentage of agreement in both adults and caregivers of children with AD. In the ANCOVA models, the scores did not differ significantly according to AD severity, consultation with a doctor, or the presence of AD in adults and caregivers but significantly differed by sex and age (both p < 0.001) in adults.</p><p><strong>Conclusion: </strong>We obtained the latest TOPICOP scores that were independent of AD conditions in Japan. Most adults and caregivers of children with AD had TCS phobia, regardless of the AD conditions. Periodic education may be required for a wide range of patients and caregivers to ease TCS phobia and enable them to continue appropriate AD treatment.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1851-1865"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126417/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01439-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Topical corticosteroid (TCS) phobia, which tends to interfere with the continuation of TCS treatment for atopic dermatitis (AD), has not been elucidated in Japan using the topical corticosteroid phobia (TOPICOP) scale. We aimed to clarify TCS phobia among patients with AD in Japan and evaluate its relationship with AD conditions.

Methods: This observational study, using the database of health receipt (between October 2021 and October 2022) and online questionnaire (conducted in October 2022) data, included adult respondents with and without AD and caregivers who responded to the questionnaire about their children aged ≤ 18 years, with and without AD. The TOPICOP scores measuring TCS phobia were summarized and compared according to AD severity, consultation with a doctor, and presence of AD using an analysis of covariance (ANCOVA) model (covariates: sex and age).

Results: In this study, 1507 adults with AD and 525 caregivers of children with AD were included. Among adults with AD, the mean TOPICOP score (± standard deviation) was 42.5 ± 18.9, while it was 41.7 ± 18.6 among caregivers of children with AD. Of the three TOPICOP domains (knowledge and beliefs, fears, and behaviors), the fear domain questions showed the highest percentage of agreement in both adults and caregivers of children with AD. In the ANCOVA models, the scores did not differ significantly according to AD severity, consultation with a doctor, or the presence of AD in adults and caregivers but significantly differed by sex and age (both p < 0.001) in adults.

Conclusion: We obtained the latest TOPICOP scores that were independent of AD conditions in Japan. Most adults and caregivers of children with AD had TCS phobia, regardless of the AD conditions. Periodic education may be required for a wide range of patients and caregivers to ease TCS phobia and enable them to continue appropriate AD treatment.

使用TOPICOP评分对日本成人和儿童特应性皮炎护理者皮质类固醇恐惧的观察研究
外用皮质类固醇(TCS)恐惧倾向于干扰TCS治疗特应性皮炎(AD)的继续,在日本尚未使用外用皮质类固醇恐惧(TOPICOP)量表加以阐明。我们的目的是澄清日本AD患者的TCS恐惧,并评估其与AD病情的关系。方法:本观察性研究使用健康收据数据库(2021年10月至2022年10月)和在线问卷(2022年10月进行)数据,包括患有和不患有阿尔茨海默病的成年受访者以及对年龄≤18岁,患有和不患有阿尔茨海默病的儿童进行问卷调查的照顾者。使用协方差分析(ANCOVA)模型(协变量:性别和年龄)对测量TCS恐惧的TOPICOP评分进行汇总和比较,并根据AD严重程度、医生咨询情况和AD存在情况进行比较。结果:本研究共纳入1507名成人AD患者和525名AD患儿的照顾者。成人AD患者的TOPICOP平均评分(±标准差)为42.5±18.9,而儿童AD患者的TOPICOP平均评分为41.7±18.6。在三个TOPICOP领域(知识和信念,恐惧和行为)中,恐惧领域的问题在成人和阿尔茨海默病儿童的照顾者中显示出最高的同意百分比。在ANCOVA模型中,根据AD的严重程度、医生咨询情况或成人和护理人员是否存在AD,得分没有显着差异,但性别和年龄存在显着差异(均为p)。结论:我们获得了最新的TOPICOP评分,该评分独立于日本的AD情况。大多数患有AD的儿童的成人和照顾者都有TCS恐惧症,无论AD的情况如何。可能需要对广泛的患者和护理人员进行定期教育,以缓解TCS恐惧症,并使他们能够继续适当的AD治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Dermatology and Therapy
Dermatology and Therapy Medicine-Dermatology
CiteScore
6.00
自引率
8.80%
发文量
187
审稿时长
6 weeks
期刊介绍: Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信